RESULTS	In additional analyses : early skin reactions in patients receiving cetuximab did not significantly affect these QoL scales , and tumour response was more common ( 58 % versus 40 % , P = 0.0002 ) and survival longer ( Hazard ratio 1.68 , P < 0.0001 ) in asymptomatic compared with symptomatic patients at baseline .\